Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Moderna Enzymatics Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently on record. This single action is assigned to 1 distinct examiner, reflecting a highly concentrated point of contact within the patent office. The prosecution is situated in 1 distinct art unit, which suggests the company's enzymatic or biological technology falls under a specific specialized classification. This concentration of activity in a single unit simplifies the tracking and management of the portfolio's current legal status.
The busiest examiner for the company is LIPPOLIS, ALEXANDRA ROSE, who is handling 1 busiest examiner pending office action. Because the total number of pending office actions is also 1, this examiner is responsible for the entirety of the company's current workload. For a practitioner, this means that the outcome of the company's current prosecution efforts depends entirely on the interaction with this one individual. The presence of 1 distinct examiner and 1 distinct art unit indicates a very specific technical focus for the company's current filings. The results of this 1 pending office action will be the primary indicator of success in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 1 | 48.7% | +61.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685259 | Method for Producing Circular DNA | LIPPOLIS, ALEXANDRA ROSE | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685259 | Method for Producing Circular DNA | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102 | Non-Final OA | — | Pending | Feb 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialModerna Enzymatics Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Alexandra Rose Lippolis has the most, with 1 of Moderna Enzymatics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.